About Peptide chain release factor 1-like, mitochondrial
Peptide chain release factor 1-like, mitochondrial (MTRF1L) is a protein
from Homo sapiens identified by UniProt accession
Q9UGC7, 380 residues long.
MolForge cross-references it against 0 known binders and
24 disease associations.
Target properties
| Protein name | Peptide chain release factor 1-like, mitochondrial |
| UniProt accession | Q9UGC7 |
| Gene | MTRF1L |
| Organism | Homo sapiens |
| Length | 380 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (24)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.53
- chronotype measurement · score 0.27
- lysosomal storage disease · score 0.24
- monocyte percentage of leukocytes · score 0.13
- body mass index · score 0.09
- self reported educational attainment · score 0.08
- neutrophil count · score 0.08
- mathematical ability · score 0.07
- glucose measurement · score 0.06
- prostate carcinoma · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UGC7-F1 | alphafold | PREDICTED | 83.75 | — |
Amino-acid sequence (380 residues)
MRSRVLWGAA RWLWPRRAVG PARRPLSSGS PPLEELFTRG GPLRTFLERQ AGSEAHLKVR RPELLAVIKL LNEKERELRE TEHLLHDENE DLRKLAENEI TLCQKEITQL KHQIILLLVP SEETDENDLI LEVTAGVGGQ EAMLFTSEIF DMYQQYAAFK RWHFETLEYF PSELGGLRHA SASIGGSEAY RHMKFEGGVH RVQRVPKTEK QGRVHTSTMT VAILPQPTEI NLVINPKDLR IDTKRASGAG GQHVNTTDSA VRIVHLPTGV VSECQQERSQ LKNKELAMTK LRAKLYSMHL EEEINKRQNA RKIQIGSKGR SEKIRTYNFP QNRVTDHRIN KTLHDLETFM QGDYLLDELV QSLKEYADYE SLVEIISQKV
Explore Peptide chain release factor 1-like, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets